Pulse Explore Journal Club Debates Trending Researchers

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

Ibrutinib and Venetoclax for First-Line Treatment of CLL | Synapse

May 29, 2019Open Access

View Full Paper

Ibrutinib and Venetoclax for First-Line Treatment of CLL

Key Points

Key points are not available for this paper at this time.

Abstract

In this study, combined venetoclax and ibrutinib was an effective oral regimen for high-risk and older patients with CLL. (Funded by AbbVie and others; ClinicalTrials.gov number, NCT02756897.).

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Jain et al. (Wed,) studied this question.

synapsesocial.com/papers/69d6ba7f8dca315383ed8af5 https://doi.org/https://doi.org/10.1056/nejmoa1900574

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Selecting Frontline Therapy for CLL in 20182018 · 16 citations
2Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (iFCG) for Firstline Treatment of Patients with CLL with Mutated IGHV and without TP53 Aberrations2018 · 18 citations
3Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study2018 · 206 citations
4Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience2018 · 387 citations
5A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL2017 · 82 citations